DJ Kerr
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 5%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
Papers in
- Hepatology 11
- Hepatocellular Carcinoma Treatment and Prognosis 11
- Co-authors
- CS McArdleJ. H. McKillopN. WillmottTessa L. HolyoakeIB PragnellSally A. LorimoreEG WrightGerard J. Graham
- Journals
- British Journal of Cancer (18 papers)Journal of Clinical Oncology (7 papers)European Journal of Cancer (6 papers)Annals of Oncology (4 papers)British journal of surgery (2 papers)
- Partner nations
- United KingdomAustraliaUnited States
In The Last Decade
DJ Kerr
53 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 99
- Hepatology 261
- Oncology 598
- Microbiology 14
- Pathology and Forensic Medicine 179
- Hematology 86
Countries citing papers authored by DJ Kerr
This map shows the geographic impact of DJ Kerr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by DJ Kerr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites DJ Kerr more than expected).
Fields of papers citing papers by DJ Kerr
This network shows the impact of papers produced by DJ Kerr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by DJ Kerr. The network helps show where DJ Kerr may publish in the future.
Co-authors
The 25 scholars most cited alongside DJ Kerr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Evaluation of PIK3CA mutation as a predictor of benefit from NSAID therapy in colorectal cancer | 2013 | 7 |
| 2 | A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (PTS) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH PTS | 2006 | 2 |
| 3 | 2001 | 3 | |
| 4 | 2000 | 74 | |
| 5 | 2000 | 17 | |
| 6 | 1997 | 20 | |
| 7 | 1994 | 35 | |
| 8 | 1994 | 18 | |
| 9 | 1992 | 7 | |
| 10 | 1992 | 1 | |
| 11 | 1992 | 69 | |
| 12 | 1992 | 5 | |
| 13 | 1992 | 6 | |
| 14 | 1992 | 21 | |
| 15 | 1990 | 17 | |
| 16 | 1990 | 57 | |
| 17 | 1988 | 9 | |
| 18 | 1988 | 48 | |
| 19 | 1988 | 19 | |
| 20 | Tumours of the diffuse endocrine system. | 1987 | 4 |
About DJ Kerr
DJ Kerr is a scholar working on Hepatology, Microbiology, Oncology, Hematology and Biomaterials, having authored 53 papers that have together received 1.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (19 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Cancer Treatment and Pharmacology (9 papers), Gastric Cancer Management and Outcomes (6 papers), Nanoparticle-Based Drug Delivery (5 papers), Renal cell carcinoma treatment (4 papers), Colorectal Cancer Surgical Treatments (4 papers) and Intraperitoneal and Appendiceal Malignancies (4 papers). The work is most often cited by research in Hepatology (261 citations), Oncology (598 citations), Microbiology (14 citations), Pathology and Forensic Medicine (179 citations) and Hematology (86 citations). DJ Kerr has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include CS McArdle, J. H. McKillop, N. Willmott, Tessa L. Holyoake, IB Pragnell, Sally A. Lorimore, EG Wright, Gerard J. Graham, DJ Dunlop and Stuart Kaye. Their work appears in journals such as British Journal of Cancer, Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology and British journal of surgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.